Tamizharasan Natarajan

Tamizharasan Natarajan is a prominent inventor based in Bengaluru, India. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target specific biological pathways. His work is crucial in the fight against various diseases, including malignant tumors and neurodegenerative disorders.

Latest Patents

Tamizharasan holds a patent for "Heterocyclic compounds as PRMT5 inhibitors." This patent describes compounds of Formula I, Formula Ia, and Formula Ib, along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs. These compounds are designed to inhibit PRMT5, making them valuable as therapeutic agents for diseases related to cellular growth, such as malignant tumors, schizophrenia, Alzheimer's disease, and Parkinson's disease.

Career Highlights

Tamizharasan is currently employed at Jubilant Episcribe LLC, where he continues to innovate and develop new therapeutic compounds. His expertise in medicinal chemistry has positioned him as a key player in the pharmaceutical industry. He has a strong focus on creating solutions that address critical health challenges.

Collaborations

Tamizharasan collaborates with talented professionals in his field, including Sayantani Sarkar and Manish Kumar Thakur. These collaborations enhance the research and development efforts at Jubilant Episcribe LLC, fostering an environment of innovation and discovery.

Conclusion

Tamizharasan Natarajan's contributions to the field of medicinal chemistry are noteworthy. His patent on PRMT5 inhibitors showcases his commitment to addressing significant health issues through innovative solutions. His work continues to impact the pharmaceutical landscape positively.

Profile summary based on public USPTO records.